These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29714524)

  • 1. Sources of Safety Data and Statistical Strategies for Design and Analysis: Transforming Data Into Evidence.
    Ma H; Russek-Cohen E; Izem R; Marchenko OV; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):187-198. PubMed ID: 29714524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.
    Izem R; Sanchez-Kam M; Ma H; Zink R; Zhao Y
    Ther Innov Regul Sci; 2018 Mar; 52(2):159-169. PubMed ID: 29714520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials.
    Zink RC; Marchenko O; Sanchez-Kam M; Ma H; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):141-158. PubMed ID: 29714519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
    Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
    Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine safety evaluation: Practical aspects in assessing benefits and risks.
    Di Pasquale A; Bonanni P; Garçon N; Stanberry LR; El-Hodhod M; Tavares Da Silva F
    Vaccine; 2016 Dec; 34(52):6672-6680. PubMed ID: 27836435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining, monitoring and combining safety information in clinical trials.
    Enas GG; Goldstein DJ
    Stat Med; 1995 May 15-30; 14(9-10):1099-111; discussion 1113-6. PubMed ID: 7569503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
    Ishiguro C; Misu T; Iwasa E; Izawa T
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
    Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
    Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
    Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA
    Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A problem-oriented approach to safety issues in drug development and beyond.
    Haas JF
    Drug Saf; 2004; 27(8):555-67. PubMed ID: 15154827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
    Ball R
    Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.